期刊
VIRUSES-BASEL
卷 9, 期 10, 页码 -出版社
MDPI
DOI: 10.3390/v9100271
关键词
apoptosis; antiviral agent; innate immunity; host response
类别
资金
- JAMP
- A Erkko foundation
- European Regional Development Fund
- Mobilitas Pluss Project [MOBTT39]
- University of Helsinki [465/51/2014]
- Academy of Finland [SA259725]
- Sigrid Juselius Foundation
- Robert A. Welch Foundation [I-1422]
- University of Lille 2 [EA3610]
- CHRU Lille
- BioAMP
- Medical Technology Development Program of the NRF
- Ministry of Science, ICT and Future Planning, Republic of Korea [1601-0302]
- JAMP
- A Erkko foundation
- European Regional Development Fund
- Mobilitas Pluss Project [MOBTT39]
- University of Helsinki [465/51/2014]
- Academy of Finland [SA259725]
- Sigrid Juselius Foundation
- Robert A. Welch Foundation [I-1422]
- University of Lille 2 [EA3610]
- CHRU Lille
- BioAMP
- Medical Technology Development Program of the NRF
- Ministry of Science, ICT and Future Planning, Republic of Korea [1601-0302]
Viral diseases remain serious threats to public health because of the shortage of effective means of control. To combat the surge of viral diseases, new treatments are urgently needed. Here we show that small-molecules, which inhibit cellular anti-apoptotic Bcl-2 proteins (Bcl-2i), induced the premature death of cells infected with different RNA or DNA viruses, whereas, at the same concentrations, no toxicity was observed in mock-infected cells. Moreover, these compounds limited viral replication and spread. Surprisingly, Bcl-2i also induced the premature apoptosis of cells transfected with viral RNA or plasmid DNA but not of mock-transfected cells. These results suggest that Bcl-2i sensitizes cells containing foreign RNA or DNA to apoptosis. A comparison of the toxicity, antiviral activity, and side effects of six Bcl-2i allowed us to select A-1155463 as an antiviral lead candidate. Thus, our results pave the way for the further development of Bcl-2i for the prevention and treatment of viral diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据